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ABSTRACT
Sarcomas are malignant tumors accounting for a high percentage of cancer 
morbidity and mortality in children and young adults. Surgery and radiation therapy 
are the accepted treatments for most sarcomas; however, patients with metastatic 
disease are treated with systemic chemotherapy. Many tumors display marginal levels 
of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a 
small non-glycosylated membrane protein overexpressed in carcinomas. The levels 
of MAP17 could be used as a prognostic marker to predict the response to bortezomib 
in hematological malignancies and in breast tumors. Therefore, we analyzed the 
expression of this oncogene in sarcomas and its relationship with clinico-pathological 
features, as well as tested whether it can be used as a new biomarker to predict the 
therapeutic response to bortezomib and new therapies for sarcomas. We found that 
the levels of MAP17 were related to clinical features and poor survival in a cohort of 
69 patients with different sarcoma types, not being restricted to any special subtype 
of tumor. MAP17 expression is associated with poor overall survival (p<0.001) and 
worse disease-free survival (p=0.002). Cell lines with high levels of MAP17 show a 
better response to bortezomib in vitro. Furthermore, patient-derived xenografts (PDX) 
with high levels of MAP17 respond to bortezomib in vivo. Our results showed that 
this response is due to the lower levels of NFκB and autophagy activation. Therefore, 
we suggest that MAP17 is a new biomarker to predict the efficacy of bortezomib as 
a new therapy for sarcomas.
INTRODUCTION
Sarcomas are rare tumors of mesenchymal origin 
[1, 2, 3]with high cancer mortality in children and young 
adults. The vast majority of sarcomas are sporadic, 
with the existence of a few genetically linked cancer 
syndromes. Furthermore, some types of environmental 
exposure have been associated with specific types of 
sarcoma [2, 3]. Taxonomical analysis of sarcomas has 
identified approximately 60 subtypes of sarcoma, as well 
as more than 50 benign tumor subtypes [4, 5]. Sarcomas 
are usually grouped into two broad categories according to 
molecular genetics: sarcomas harboring a diploid or nearly 
diploid karyotype and simple genetic driver alterations, 
such as Ewing’s sarcoma, or sarcomas with a complex 
and imbalanced karyotype, such as osteosarcoma. The 
subgroups include very different clinical entities and are 
broadly drawn, not reflecting the genetic diversity among 
tumors of a given type or subtype or their diverse tumor 
biology [4].
Surgery is the standard approved treatment for 
most resectable sarcomas. Radiotherapy is selected 
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for those unresectable or residual tumors after surgery. 
Chemotherapy is used in metastatic disease [6]. However, 
many tumors exhibit chemoresistance, and new treatments 
are needed. Systemic therapies for sarcomas include 
doxorubicin, gemcitabine, ifosfamide and the recently 
accepted drug trabectedin [7–10]. To date, few direct 
targets for therapy have been demonstrated in sarcomas, 
in contrast to those for epithelial cancers. The exceptions 
are GISTs, in which imatinib, the c-Kit kinase inhibitor, 
induces a partial response or stable disease in most sarcoma 
patients [4]. These findings support the hypothesis that 
widely diverse sarcoma tumors may share a dependence 
on a particular protein and that this marker may, therefore, 
be expected to be effective for all histological subtypes 
that are positive for this biomarker. We have recently 
extended this observation for CDK inhibition. We have 
found that sarcoma tumors with combined high levels of 
CDK4 mRNA and low levels of p16INK4a, respond to 
palbociclib (a CDK4 inhibitor) in a panel of PDX models 
in vivo, irrespective of the tumor type [11].
MAP17 (DD96, PDZKIP1), a membrane-associated 
protein with a molecular weight of 17 kD [12–14], is 
expressed only in the cells of the proximal tubule of the 
adult kidney [15–17]. It contains two transmembrane 
regions and a hydrophobic N-terminus encoding one 
PDZ-binding domain [18, 19]. Through this domain, 
MAP17 has been demonstrated to bind proteins containing 
PDZ domains, including PDZK1 (NHRF3), and other 
NHRF-related proteins, such as NaPiIIa and NHe3 [15, 
17, 19]. MAP17 increases the cellular reactive oxygen 
species (ROS), which have been shown to enhance the 
malignant properties of tumor cells [20–22]. Tumor cells 
overexpressing MAP17 show increased proliferation, 
reduced apoptosis, increased formation in soft agar 
and increased growth of tumors in nude mice [20, 22]. 
However, the inhibition of ROS by antioxidant treatments 
can prevent the enhancement of the pro-tumorigenic 
properties of cells [14]. MAP17 is overexpressed in most 
human carcinomas and in other non-epithelial neoplasias 
such as glioblastomas or lymphomas [23]; additionally, 
its expression is associated with progression [17, 23, 24]. 
While adenomas and benign tumors, as well as normal 
tissues, rarely express MAP17, a high proportion (50 to 
90%) of late-stage or metastatic tumors show high levels 
of MAP17, correlating with a more de-differentiated 
phenotype [17, 22, 24–26]. These findings highlight the 
relevance of this gene in the process of tumorigenesis and 
development of tumors.
MAP17, through an as-yet-unknown mechanism, 
increases ROS in cells. This ROS increase may be 
responsible, at least partly, for the enhanced malignant 
properties induced in tumor cells [33]. Because ROS is a 
potent proapoptotic insult, a further increase of ROS might 
switch the balance towards apoptosis. Thus, tumors with 
high MAP17 levels may respond to therapies increasing 
ROS. Therefore, MAP17 expression levels may be a 
suitable biomarker for prognosis. Cervix tumor patients 
treated with cisplatin and radiotherapy showed better 
survival if the tumor showed high levels of MAP17 
[24, 27, 28]. Therefore, MAP17 is not only a marker for 
stage and malignant status but also may be a marker of 
response to therapies, inducing oxidative stress. In breast 
tumor cells, the MAP17 expression level determines the 
sensitivity to bortezomib by inhibiting the cytoprotective 
effects resulting from bortezomib-induced NFκB nuclear 
translocation and autophagy [29]. Furthermore, the 
inhibition of oxidative stress abolishes the MAP17-
induced sensitivity to bortezomib. Therefore, high levels 
of MAP17 could be used for predicting bortezomib 
treatment responses in patients.
In this manuscript, we have explored the relevance 
of the presence of MAP17 in sarcoma tumors where the 
primary response is mainly achieved by treatments with 
radiotherapy. We found that, in contrast to laryngeal and 
cervix adenocarcinomas, the expression of MAP17 is a 
poor prognostic factor. Therefore, as we are looking for 
new therapeutic modalities for sarcomas, we have tested 
whether high levels of MAP17 may be a determinant in 
the response to bortezomib.
RESULTS
Clinical cohort description
The patient cohort with a clinical follow up had 
equal distribution by gender with 53% males and 47% 
females, with an average of 51 years at the time of 
diagnosis (Table 1). However, they showed a broad 
distribution in age, from 20 to 72 years. The histology 
was very variable with liposarcoma at 18.8% (n=13), 
undifferentiated pleomorphic sarcoma at 17.4% (n= 
12) and leiomyosarcoma at 31.9% (n=22) as the most 
prevalent. Other types of minor represented sarcomas 
in our cohort were hemangiopericytoma at 4.3% (n=3), 
synovial sarcoma at 4.3% (n=3), neurogenic sarcoma at 
4.3% (n=3), fibrosarcoma at 7.2% (n= 5), fibromyxoid 
sarcoma at 1.5% (n=1), angiosarcoma at 1.5% (n=1), and 
mesenchymal sarcomaat1.5% (n=1). These tumors were 
mostly metastatic at the time of diagnosis (76%), and 
the remainder was locally advanced. The treatment was 
doxorubicin 75 mg/m2 3w x 6 cycles in all cases with half 
of the cases in combination with trabectedin 1.1 mg/m2 + 
doxorubicin 60 mg/m2 3w x 6 cycles 49.3% (n=34). This 
cohort has been reported in Martin-Broto et al [30].
Only for IHC analysis of MAP17 expression was 
this series completed with complementary samples (for 
which we do not have clinical information) used to assess 
MAP17 values in different sarcoma types (Supplementary 
Table S1).
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Table 1: Clinical characteristics of the patients
Patients (N=69)
Gender
 Male 53.6 (37)
 Female 46.4 (32)
Age (years) 51 [20-72]
Histology
Liposarcoma 18.8 (13)
Undifferentiated Pleomorphic Sarcoma 17.4 (12)
Haemangiopericytoma 4.3 (3)
Leiomyosarcoma 31.9 (22)
Synovial Sarcoma 4.3 (3)
Neurogenic Sarcoma 4.3 (3)
Fibrosarcoma 7.2 (5)
Unclassified Sarcoma 5.8 (4)





Locally advanced 23.2 (16)
Metastatic 76.8 (53)
Treatment
Doxorubicin 75 mg/m2 3w x 6 cycles 50.7 (35)
Trabectedin 1.1 mg/m2 + Doxorubicin/ 3w 60 mg/m2 3w x 
6 cycles
49.3 (34)
MAP17 Expression in human sarcoma
We analyzed 69 samples, for which we had 
clinical information, for MAP17 expression by 
immunohistochemistry (Figure 1), finding the percentage 
of tumors with high levels of expression as in other tumor 
types [17]. Using 0,75 as the cut-off level of MAP17 
expression as depicted by the ROC curve (Figure 2), with 
a sensitivity = 0,76 and a specificity = 0,56, we found that 
high levels of MAP17 are predictive of a worse disease-
free survival (DSF, p=0,03) and worse progression-free 
survival (PSF, p=0,033); however, there was no relevance 
regarding overall survival (OS) (Figure 2). These patients 
were treated with doxorubicin alone or with doxorubicin 
plus trabectedin. The analysis of the DFS, PFS or OS 
in these patients sorted by treatment scheme shows a 
similar trend in patients treated only with doxorubicin 
(Supplementary Figure S1A); in patients treated with the 
combination of doxorubicin plus trabectedin, MAP17 
did not show any prognostic relevance (Supplementary 
Figure S1B).
One hundred one tumor samples were analyzed for 
MAP17 expression by immunohistochemistry. Of the 101 
samples, 39% showed higher levels of MAP17 protein 
expression and were considered positive for MAP17 
expression (Figure 3A) according to the previous ROC 
curve performed. The distribution of tumors with MAP17 
was broad and was not restricted to any specific sarcoma 
type (Figure 3B), but there was a direct correlation of the 
levels of MAP17 with tumor grade (ANOVA, p<0.05) 
(Figure 3C), which was statistically significant. The 
surrounding normal tissue did not express MAP17 or 
expressed very low levels.
The analysis of the impact on DFS, PFS or 
OS on specific sarcoma types such as liposarcoma, 
undifferentiated or leiomyosarcoma, showed a similar 
trend to the total population comprising all sarcoma types 
(Supplementary Figure S2). However, the small number 
of cases precludes any strong conclusion. Furthermore, 
the analysis of databases for the expression of MAP17 
in other types not sufficiently represented in our cohort, 
such as osteosarcoma or Ewing’s sarcoma with a high 
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Figure 2: Relationship of the MAP17 levels with the clinical response in sarcomas. ROC curve for MAP17 showing that, 
at the cut-off point of MAP17>0,75, the sensitivity=0.76 and thespecificity=0.56. Correlation of the MAP17expression was measured as 
a dichotomous variable: MAP17 high rates (>0,75) with overall survival (OS), disease-free survival (DFS) and progression free survival 
(PFS).
Figure 1: Representative pictures of MAP17-stained sarcoma samples. Angiosarcoma (AS), Leiomyosarcoma (Ly), GIST 
(Gist), pleomorphic sarcoma (Plm), chondrosarcoma (CS), Ewing’s sarcoma (EW).
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MAP17 level, also shows a worse prognosis in either OS 
or metastasis-free survival (Supplementary Figure S3).
Therefore, our data showed that 40% of sarcomas 
display high levels of MAP17 protein at the time of 
diagnosis, unrelated to the specific tumor type. High levels 
of MAP17 are related to a higher grade and are predictive 
of a poor prognosis in patients with sarcoma.
Furthermore, multivariate analysis indicated that 
MAP17 is an independent predictor of the sarcoma 
outcome (Table 2).
The response to bortezomib in sarcoma cell lines 
correlates with MAP17 Levels
Because these patients with high MAP17 showed 
a worse prognosis, we wondered whether we can find an 
alternative treatment for these patients. To this end, we 
planned to test bortezomib, which showed efficacy in 
breast tumor cells if MAP17 is overexpressed [29]. Thus, 
we first analyzed the role of MAP17 levels in sarcoma 
cell lines.
To explore the effect of MAP17 on the response 
to bortezomib, we used a panel of 16 sarcoma cell lines 
of heterogeneous origin [11, 31, 32]. We treated them 
at different concentrations of bortezomib and obtained 
an IC50 value for each one. All of the responses were in 
the nM range (Table 3), distributed however in a 50-fold 
range, between 10 and 500 nM. In parallel, we measured 
the basal levels of MAP17 mRNA in all cell lines (Table 
3) and found different expression levels between them. 
We distributed the cell lines into three groups according 
to the MAP17 mRNA level: those with barely detectable 
MAP17 mRNA (BP, CE, CD0024, SAOS2, SK-UT-1, HT-
1080 and CP0038), those with low but clearly detectable 
levels of MAP17 mRNA (AA, AW, BG and BD) and those 
with high levels of expression (BC, AZ, AX, SW872 and 
93T449). The analysis of the correlation of the MAP17 
mRNA levels and IC50 to bortezomib showed a trend 
Figure 3: MAP17 expression in sarcoma tumors. A. Overall distribution of MAP17-positive sarcomas. B. MAP17 level 
distribution among different sarcoma types. Angiosarcoma (AS), fibromyxoid sarcoma (FM), fibrosarcoma (F), hemangiopericytoma 
(HP), leiomyosarcoma (Ly), liposarcoma (L), neurogenic sarcoma, MPNST (N), synovial sarcoma (Sy), undifferentiated pleomorphic 
sarcoma (UPl), Ewing’s sarcoma (Ew), rhabdomyosarcoma (R), fusocellular sarcoma (Fs), GIST (G), pleomorphic sarcoma (Plm), and 
chondrosarcoma (CS). C. Map17 levels correlate with tumor grade in sarcoma. The mean values are represented for grade 1 (=0,45), grade 
2 (=0,66) and grade 3 (0,90). ANOVA was performed to establish the statistical association between the MAP17 protein levels and grade 
of the tumor (p<0,05).
Oncotarget67038www.impactjournals.com/oncotarget
(ANOVA, p=0,1) indicating that cells with higher levels 
of MAP17 are more sensitive to bortezomib than cells 
without MAP17 (Figure 4A).
To functionally confirm these data, we 
overexpressed MAP17 cDNA in 2 sarcoma cell lines 
with very low expression, AA and AW (Figure 4B), and 
calculated a new IC50 to bortezomib in these cell lines and 
compared to parental cells expressing empty vector only. 
We found that the ectopic expression of MAP17 increases 
the sensitivity to bortezomib 2-3 fold (Figure 4C). To fully 
confirm these results, we reduced the levels of MAP17 
in the AX sarcoma cancer cell line, which shows high 
endogenous levels of MAP17. We overexpressed an 
shRNA against MAP17 and reduced the levels of MAP17 
to 50% (Figure 4D), and then we tested the bortezomib 
sensitivity (Figure 4E). We observed a 50% reduction in 
Table 3: IC50 to bortezomib of the panel of sarcoma cell lines used in this study and its correlation to the levels of 
MAP17 mRNA measured by RT-QPCR
Cell line Tumor of origin IC50 Bortezomib (μM) MAP17 (2-ΔCT)
93T449 Liposarcoma 35,9±3,75 0,000182199
AA Leiomyosarcoma 20,65±0,75 6,21882E-05
AW Liposarcoma 30,95±8,5 0,00011437
AX Liposarcoma 19,3±5,2 0,000534323
AZ Fibrosarcoma 92,89±0,92 0,001050201
BC MPNST 32,5±9,8 0,00025699
BD Ewing’s Sarcoma 149,7±17,42 0,000111012
BG Myxoid Fibrosarcoma 28,99±5,8 7,64036E-05
BP Osteosarcoma 502±56,6 2,32244E-05
CE Rhabdomyosarcoma 15,53±2,9 4,55244E-05
CP0024 Leiomyosarcoma 30,75±5,46 2,84148E-05
CP0038 Leiomyosarcoma 43,65±9,78 2,52213E-05
HT1080 Fibrosarcoma 15,88±2,37 1,68955E-05
Saos-2 Osteosarcoma 52,78±9,5 1,30192E-05
SKUT1 Uterine Leiomyosarcoma 10,95±2,46 4,58532E-05
SW872 Liposarcoma 10,13±2,36 0,000262208
IC50 is the average of 3 independent experiments performed in triplicate. To measure human MAP17 RNA expression, 
real-time PCR was performed using a ABI 7900HT (Applied Biosystems), and we used GADPH as internal control/
reference. Quantitative and statistical analyses of the QPCR data were calculated using Applied Biosystem RQ Manager 
1.2.1 software. We presented the 2eΔΔCT data. The levels of MAP17 mRNA presented are the average of the mRNA levels 
obtained in three independent determinations performed in triplicate samples.









MAP17 -0.268 0.015 -0.268 0.016 -0.142 0.129
Radiotherapy -0.155 0.134 -0.143 0.154 0.162 0.123
Differentiation -0.216 0.06 -0.167 0.116 -0.245 0.038
Metastatic 
disease -0.191 0.085 -0.125 0.187 -0.207 0.069
T4 extension -0.114 0.208 -0.157 0.130 -0.207 0.069
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the sensitivity, comparable to the 2-fold increase observed 
in the cell lines with enforced overexpression of MAP17.
Sarcomas overexpressing MAP17 are more 
sensitive to bortezomib in vivo
Therefore, we decided to test the response of 
sarcomas to bortezomibin patient- derived xenografts, 
PDXs, in vivo. Of a panel of sarcoma PDXs [11], we 
selected 4 models (Figure 5A) with different levels of 
MAP17 (Figure 5B). Twelve mice were implanted for 
each PDX model and were randomly distributed for the 
treatment with bortezomib or solvent alone (PBS). We 
found that the PDX with high levels of MAP17 showed 
a better response to bortezomib (Figure 5C). The tumor 
disappeared from the flank of all mice treated with 
bortezomib, and the mice survived. The PDX model S11, 
with still significant but low levels of MAP17, partially 
responded to bortezomib by decreasing the tumor growth 
rate and increasing survival by 25% approximately (Figure 
5C). However, the models with low or no MAP17 (S14 
and S29) did not respond to bortezomib (Figure 5C). 
Thus, our data in vivo, in PDX models of sarcoma, support 
our data in vitro and suggest that bortezomib may be a 
suitable therapy for sarcoma patients with high MAP17 
at diagnosis.
We have previously shown that MAP17 prevents 
cytoprotective NFκB activation and autophagy induced 
by bortezomib in breast tumor cells [29]. Therefore, we 
have tested whether these molecular markers correlate 
also in our PDX models prior to treatment (Figure 6A). 
S16, the PDX model that responds to bortezomib, showed 
lower levels of endogenous active NFκB (measured as p65 
phosphorylated at Ser536) and autophagy (measured as 
p62 and/or LC3 increase), thus confirming the mechanistic 
role of these factors in the bortezomib response. Similar 
data could be observed in the AA and AW cell lines, where 
the overexpression of MAP17 reduces NFκB activation 
Figure 4: Correlation of the MAP17 levels with the sensitivity to bortezomib. A. Correlation of the MAP17 levels with 
the sensitivity to bortezomib in a panel of 16 sarcoma cell lines. The cell lines were subdivided according to the levels of MAP17: no or 
barely detectable levels of MAP17 mRNA= Low (BP, CE, CP0024, SAOS2, SK-UT-1, HT-1080 and CP0038); cells with low but clearly 
detectable levels of MAP17 mRNA= medium (AA, AW, BG and BD); and high levels of expression= high (BC, AZ, AX, SW872 and 
93T449). The analysis of the correlation of MAP17 mRNA levels and IC50 to bortezomib was performed with ANOVA, p=0,1. B. Levels 
of MAP17 mRNA in cell lines ectopically expressing MAP17 cDNA (MAP17) or vector only (V). The data show the average levels of 
MAP17 mRNA by Q-RT-PCR, performed in three independent determinations. C. Curves showing the IC50 of cell lines ectopically 
expressing MAP17 cDNA (MAP17) or vector only (V). IC50 in the inset is the average ± SD from 4 independent experiments performed 
in triplicate. D. Decrease of the levels of MAP17 mRNA by specific expression of shmRNS against MAP17 in the sarcoma cell line AX. 
The data show the average levels of MAP17 mRNA by Q-RT-PCR, performed in three independent determinations. E. Curves showing 
the IC50 of cell lines ectopically expressing MAP17 sh mRNA (shM17) or scramble shRNA as control (Scr M17). IC50 in the inset is the 
average ± SD from 3 independent experiments performed in triplicate.
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Figure 5: Effect of bortezomib on sarcoma tumors in vivo. A. PDX models used in this study. B. Levels of MAP17 mRNA in 
each model. C. Response to bortezomib. The left graph shows the average ±SD of tumor growth. The right graph shows the survival of the 
mouse cohorts with sacrifice by humane endpoint when the tumor reaches 1000 mm3. The sarcomas were subcutaneously engrafted and 
grown until all of the tumors reached 20 mm3 in volume. The mice were then treated for 4 weeks (5 days/eek). The cohorts of mice were 
either treated with bortezomib (1.0 mg/kg body weight, in 0.9% NaCl) or saline serum (0.9% NaCl). The mice were monitored daily for 
signs of distress and were weighed twice a week. The tumor size was measured using a caliper according to the following equation: tumor 
volume = [length x width2]/2. The experiments were terminated when the tumor reached 1000 mm3.
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and autophagy (Figure 6B, Supplementary Figure 
S4A). Moreover, we observed that MAP17 prevents the 
cytoprotective activation of NFκB and autophagy induced 
by bortezomib (Figure 6C, Supplementary Figure S4B) 
in sarcoma cell lines, a finding that has been reported 
previously for breast tumor cells [29]. Therefore, the 
inhibition of these protective pathways induced by MAP17 
may explain the increase in sensitivity to bortezomib 
found in vivo.
DISCUSSION
High MAP17 levels correlate with a higher grade 
and poorer differentiation of tumors; therefore, therapies 
that can counteract MAP17 expression may lead to the 
promising application of known treatments to tumors with 
a poor prognosis. Sarcoma tumors that express MAP17 
have a poor prognosis independent of the tumor origin. 
However, sarcoma cell lines and PDX tumors in vivo with 
high levels of MAP17 respond to the proteasome inhibitor 
bortezomib (Velcade, PS-341), approved by the FDA 
for the treatment of mantle cell lymphoma and multiple 
myeloma [33, 34]. Thus, our work provides first evidence 
that certain patients may benefit from this therapy that 
could be newly applied to second- or third-line sarcoma 
patients, currently without any other therapeutic option.
MAP17 maintains a functional relationship with 
the proteasomal degradation pathway [29]. Used as a 
“seed”, MAP17 was found to be linked to proteins related 
to degradation pathways, mainly ubiquitination- and 
sumoylation-related pathways. We found that multiple 
myeloma patients with higher MAP17 mRNA levels 
Figure 6: Levels of NFκB and autophagy in sarcoma tumors or cell lines expressing MAP17. A. Western blots showing 
the levels of different basal protein levels in sarcoma PDX models. NFκB-p65 phosphorylated at Ser536, total NFκB-p65, LC3B and 
p62. Treatment with bortezomib was performed for 24 hrs. B. Quantification of Figure 6A, cell line AA. C. Quantification of Figure 6A, 
cell line AW. D. Western blots showing the levels of different proteins in AA and AW sarcoma cell lines overexpressing MAP17 or empty 
vector only. NFκB-p65 phosphorylated at Ser536, total NFκB-p65, LC3B and p62. Quantification is shown in Figure 4A. E. Western blots 
showing the levels of different proteins in AA and AW sarcoma cell lines overexpressing MAP17 or empty vector only, in response to 
bortezomib (+) or to solvent only (-). NFκB-p65 phosphorylated at Ser536, LC3B and p62 levels are shown. Quantification is shown in 
Figure 4B.
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respond better to bortezomib and exhibit prolonged 
survival [29]. We also showed that MAP17 determines 
the bortezomib sensitivity by inhibiting the cytoprotective 
effects related to bortezomib-induced NFκB nuclear 
translocation and autophagy. Therefore, high levels of 
MAP17 could be used to select some patients for which 
bortezomib is not currently indicated, such as sarcoma, but 
who could benefit from this therapy.
We found that the MAP17-dependent increase in 
sensitivity in sarcoma was correlated with lower levels 
of phosphorylated NFκB and autophagy measured as 
p62/LC3II, further supporting the relevance of these two 
pathways in MAP17 increased sensitivity. Therefore, 
the inhibition of autophagy or NFκB pathways may also 
cooperate with bortezomib in the response to sarcomas. 
It will be of interest to test the response to bortezomib, 
or other proteasome inhibitors [35], in combination with 
autophagy or NFκB inhibitors in MAP17-expressing 
sarcomas.
MAP17 is mainly expressed in advanced tumor 
stages but not in normal tissue, benign tumors (adenomas) 
or early-stage neoplasias [23]. In all human tumors, 
MAP17 is an independent prognosis marker. MAP17 
overexpression correlates with advanced stages in 
ovarian, cervical, laryngeal and prostate tumors [23]. 
Mammary tumor cells that express MAP17 show an 
enhanced tumor phenotype, which is characterized by 
enhanced proliferative capabilities [22]. The increased 
tumorigenic properties caused by the expression of 
MAP17 are associated with high levels of ROS, and 
the inhibition of antioxidants decreases their malignant 
properties. Inhibition of ROS with antioxidant treatments 
also inhibits the effect of MAP17 on NFκB activation 
and autophagy, restoring resistance to bortezomib and 
indicating that ROS are involved in this process. It has 
been shown that bortezomib favors the unfolded protein 
response (UPR), which is activated in response to 
alterations in the ER physiological environment [36–38]. 
This ER stress stimulates ROS production, which alters 
the responses to bortezomib treatment in patients with 
MCL [38] and MM [39]. The MAP17-induced increase 
in ROS is also functionally related to NHeRFs. Inhibition 
of these transporters by furosemide impairs the response 
to bortezomib, thus leading to the recovery of bortezomib 
resistance in MAP17-overexpressing cells [29]. Currently, 
there are several clinical trials with bortezomib as 
monotherapy or in combination with other drugs in 
sarcoma patients [40, 41]. It will be interesting to analyze 
the results of the trials in relation to MAP17 expression.
In sarcoma, MAP17 is a marker for poor DFS 
irrespective of the tissue type, indicating that MAP17 has 
no role in the response to current treatments, including 
doxorubicin alone or in combination with trabectedin. 
However, in laryngeal and cervical tumors, MAP17 is a 
potent marker for better prognosis, including longer overall 
survival [24, 27, 42]. In cervical cells, the overexpression 
of MAP17 makes these cells more sensitive to cisplatin 
and/or radiotherapy [24, 27], explaining the enhanced 
sensitivity. However, sarcomas are primarily managed 
by surgery and/or radiation, being this last treatment 
modality mainly used in the neo-adjuvant or adjuvant 
setting in combination or not with systemic therapies [6]. 
We do not have adequate information to study the role of 
MAP17 as a prognostic marker in un-resectable tumors 
treated with radiotherapy, alone or in combination with 
other chemotherapies such as ifosfamides, but it certainly 
deserves attention. Our own preliminary data suggest that 
sarcoma cells expressing MAP17 are also more sensitive 
to ROS-inducing therapies such as cisplatin (unpublished 
observation).
High MAP17 levels correlate with a higher grade 
and poorer differentiation of sarcoma, and tumors that 
express MAP17 at diagnosis have a poor prognosis 
independent of the tumor origin. However, sarcoma cell 
lines and PDX tumors in vivo with high levels of MAP17 
respond to the proteasome inhibitor bortezomib [33, 34]. 
Thus, our work provides the first evidence that certain 
patients may benefit from this therapy that could be newly 
applied to second- or third-line sarcoma patients, currently 
without any other therapeutic option.
MATERIALS AND METHODS
Tumor samples for immunohistochemistry 
studies
The cohort of 69 patients for immunohistochemistry 
studies and the correlation of clinico-pathological features 
(Table 1) were obtained from the Sarcoma Research 
Spanish Group Trial 20, Geis 20 [30]. For the study 
of the MAP17 expression of different sarcoma types 
(Figure 3B), this cohort was complemented with 24 extra 
samples (Supplementary Table S1) obtained from tumor 
tissues obtained from the surgical resection of sarcomas 
performed at University Hospital Virgen del Rocio 
(Seville, Spain). All of the patients provided written 
informed consent according to a protocol approved by 
the local ethics committee (CEI 2013/PI002). All tissue 
samples and patient information were treated according to 
the Declaration of Helsinki.
Immunohistochemistry
Three-micrometer slices were sectioned from the 
TMA block and were applied to coated, immunochemistry 
slides (DAKO, Glostrup, Denmark). The slides were 
baked overnight in a 56°C oven, deparaffinized in xylene 
for 20 min, rehydrated through a graded ethanol series 
and washed with PBS. A heat-induced epitope retrieval 
step was performed by heating a slide in a solution of 
sodium citrate buffer at pH 6.5 for 2 min in a conventional 
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pressure cooker. After heating, the slides were incubated 
with proteinase K for 10 min and were rinsed in 
cool running water for 5 min. Endogenous peroxide 
activity was quenched with 1.5% hydrogen peroxide 
(DAKO) in methanol for 10 minutes, and incubation 
with the primary antibodies anti-MAP17 (1:4) [14, 20, 
22, 25] was performed for 40 min. After incubation, 
immunodetection was performed with the EnVision 
(DAKO, Glostrup, Denmark) visualization system using 
diaminobenzidinechromogen as the substrate, according 
to the manufacturer’s instructions. Immunostaining was 
performed in a TechMate 500 automatic immunostaining 
device (DAKO) and was measured through a double-
blind visual assessment using microscopic observation 
according to the anatomopathological experience 
of pathologists. Sample scoring was performed by 
semiquantitative microscopic analysis, considering 
the signal intensity. We used the score obtained by the 
intensity levels (1, 2 or 3). The threshold used is the score 
of 0,75, obtained by ROC curve as the most relevant to 
establish as a dichotomous variable.
Tumor samples for PDX generation
Tumor tissues were obtained from the surgical 
resection of sarcomas performed at University Hospital 
Virgen del Rocio (Seville, Spain). All of the patients 
provided written informed consent according to a protocol 
approved by the local ethics committee (CEI 2013/
PI002). The experiments were performed according to the 
European guidelines for laboratory animal care. This study 
was approved by the IBIS Institutional Animal Care and 
Use Committee.
PDX generation
Sarcoma tissue samples were obtained from a single 
tumor area and were preserved in Dulbecco’s modified 
Eagle’s medium nutrient mixture/F10 (DMEM/F10; 
Sigma) containing 10% fetal bovine serum, penicillin, 
streptomycin and amphotericin B (100 mg/ml each; 
Sigma). The samples were maintained for less than 
2 hours in cell culture medium at room temperature 
before implantation. Each tissue was divided into 2 
parts. One part was frozen, and the remaining part was 
cut into small fragments of 2-3 mm in diameter to be 
used for subcutaneous implantation into 6-week-old 
Foxn1nu athymic nude female mice (Harlan Laboratories, 
Netherlands). Upon reaching a size of 1,500 mm3, the 
mice were euthanized, and the tumors were re-grown in a 
similar fashion to perform the indicated experiments.
In vivo treatments
To initiate the experiments, each sample was 
xenografted into mice. Once the tumors reached 1500 
mm3, they were harvested, cut into 2x2x2-mm blocks 
and implanted. The experiments were performed using 
cohorts of 6 animals. the mice were randomly allocated to 
the drug-treated and control-treated (solvent only) groups; 
once the tumor grew to 20 mm3, the mice were treated 
for 4 weeks (5 days/week). The cohorts of mice were 
treated with either bortezomib (1.0 mg/kg body weight, in 
0.9% NaCl) or saline serum (0.9% NaCl). The mice were 
monitored daily for the signs of distress and were weighed 
twice a week. The tumor size was measured using a 
caliper according to the following equation: tumor volume 
= [length × width2]/2. The experiments were terminated 
when the tumor reached 1000 mm3.
Western blot analyses
Western blot analyses were performed as previously 
described [43, 44]. Briefly, the cells were washed twice 
with PBS and were lysed via sonication in lysis buffer 
(50 mM Tris-HCl, pH 7.5; 1% NP-40; 1 mM Na3VO4; 
150 mM NaCl; 20 mM Na
4
P2O7; 100 mM NaF; 1% Na-
deoxycholate; 0.1% SDS; 1 mM EDTA; phosphatase 
inhibitor cocktail (Sigma) and protease inhibitor cocktail 
(Sigma)). The samples were separated on 6–15% SDS-
PAGE gels, transferred to nitrocellulose membranes 
(Protran BA83; Whatman) and immunostained. The 
following primary antibodies and dilutions were used: anti- 
NFκB-p65 (1:2000; Abcam #ab16502), anti- NFκB-p65 
(phospho Ser536) [93H1] (1:1000; Cell Signaling #3033), 
anti-LC3B (1 μg/ml; Abcam #ab48394), anti-SQSTM1/
p62 (1:20000; Abcam #Ab 109012) and anti-α-tubulin 
(1:5000; Sigma 9026). Horseradish peroxidase-labeled 
rabbit anti-mouse (Amersham, diluted 1:3000) and goat 
anti-rabbit (Abcam, #6721, diluted 1:3000) secondary 
antibodies were used. The proteins were visualized using 
an ECL detection system (Amersham Biosciences).
Quantitative mRNA determination
Total RNA was isolated via cell lysis in Qiazol 
reagent using an RNA Mini Kit (Qiagen, Inc.). First-
strand cDNA synthesis was performed using 2.0 μg of 
RNA, random primers, a dNTP mix and Multiscribe 
Reverse Transcriptase in a total volume of 50 μl (High 
Capacity Transcription Kit, Applied Biosystems). The 
conditions used for RT-PCR were as follows: 10 min at 
25°C, 120 min at 37°C, and 5 min at 95°C. To measure 
human MAP17 expression, real-time PCR was performed 
using an ABI 7900HT PCR system (Applied Biosystems). 
The qPCR reactions were performed in 384-well plates via 
TaqMan Gene Expression Assays (Applied Biosystems). 
Gadph expression was examined as an internal control. 
The relative mRNA quantities were expressed as 2-ΔCt. 
The relative mRNA quantification and statistical analysis 
of qPCR data were conducted using RQ Manager 1.2.1 
software (Applied Biosystems).
Oncotarget67044www.impactjournals.com/oncotarget
Human primary sarcoma cell lines and culture 
conditions
The sarcoma cell lines used in this study were 
previously characterized [11, 31, 32]. The cells were 
maintained as a subconfluent monolayer in F-10 medium 
(Sigma) supplemented with 10% FBS, penicillin-
streptomycin antibiotics (Sigma) and Fungizone 
(Amphotericin B, Sigma). Each cell line was cultured at 
37°C and 95% humidity in 5% CO2 under conditions of O2 
levels, culture medium and supplements indicated in the 
provider’s instructions.
Transfection
Subconfluent AA and AW cells were transfected 
using the Lipofectamine method (Effectene, Qiagen) 
with 0.4 μg of the empty mammalian expression plasmid 
pBabepuro or pBabepuro containing either the wild-type 
MAP17 gene [45]. At 24 hours after transfection, the cell 
lines were cultured in F-10 medium supplemented with 
10% FBS and 2 μg/ml puromycin.
Cytotoxicity assay
Bortezomib was freshly prepared as a 30-mM stock 
solution in sterilized deionized water for each experiment. 
Bortezomib was applied to a 96-well master plate at 
decreasing concentrations of 1/3, such that 300 μM was 
the highest concentration studied. The cell lines were 
seeded in 96-well plates (5,000-10,000 cells per well, 
depending on the cell size). At 24 hours after seeding, 
treatment was applied for 96 hours. Cell proliferation 
was determined by the MTT assay and was confirmed by 
crystal violet staining [46]. The IC50 was calculated using 
GraphPad Prism software.
Statistical Analysis and Definitions
Kaplan-Meier method was used for survival 
analysis, using the Cox proportional hazards model to 
adjust for the explanatory variables, obtain the p-values 
and estimate the HR. Multivariate logistic regression 
was used to obtain the odds ratios (ORs) and confidence 
intervals (CI 95%). Pearson’s correlation measured the 
dependence between the quantitative variables. Receiver 
operating characteristic (ROC) curve analysis was 
performed to assess the MAP17 cutoff point, which we 
checked using the optimal Youden index-based point. 
In addition, the log-rank test was used to compare the 
survival distributions between the high and low MAP17 
levels. Statistical calculations were performed using SPSS 
22.0 software. OS was defined as the length of time from 
the date of diagnosis until the date of the last medical 
record.
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